More Post from the Author
- SIRUI Wins "Best of Show", Unveils New Cine Lenses at NAB Show 2026
- Akemona to Power Upcoming Tokenized Offering for Industrialized Innovation Impact Portfolio I
- La vacunacin materna contra el VRS reduce el riesgo de hospitalizacin infantil en ms del 80%
- ESCMID Global: Maternal RSV vaccination cuts infant hospitalisation risk by over 80%, major UKHSA study finds
- CGTN: Ako kultrne vmeny podporuj nsko-vietnamsk priatestvo
SNDL to Announce First Quarter 2025 Financial Results on May 1, 2025
EDMONTON, AB, April 14, 2025 /PRNewswire/ - SNDL Inc. (Nasdaq: SNDL) (CSE: SNDL) ("SNDL") announced today that it will release its first quarter 2025 financial results for the period ended March 31, 2025, before market opens on Thursday, May 1, 2025.
Following the release of its first quarter results, SNDL will host a conference call and webcast at 10:00 a.m. EDT (8:00 a.m. MDT) on May 1, 2025.
WEBCAST ACCESS
To access the live webcast of the call, please visit the following link:
https://edge.media-server.com/mmc/p/4ikuz377
ABOUT SNDL INC.
SNDL Inc. (NASDAQ: SNDL, CSE: SNDL), through its wholly owned subsidiaries, is one of the largest vertically integrated cannabis companies and the largest private-sector liquor and cannabis retailer inCanada,with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, Spiritleaf and Superette. With products available in licensed cannabis retail locations nationally, SNDL's consumer-facingcannabis brands include Top Leaf, Contraband, Palmetto, Bon Jak, La Plogue, Versus, Value Buds, Grasslands, Vacay, Pearls by Grn, No Future and Bhang Chocolate. SNDL's investment portfolio seeks to deploy strategic capital through direct and indirect investments and partnerships throughout the North American cannabis industry.For more information, please visit www.sndl.com
SOURCE SNDL Inc.

More Post from the Author
- SIRUI Wins "Best of Show", Unveils New Cine Lenses at NAB Show 2026
- Akemona to Power Upcoming Tokenized Offering for Industrialized Innovation Impact Portfolio I
- La vacunacin materna contra el VRS reduce el riesgo de hospitalizacin infantil en ms del 80%
- ESCMID Global: Maternal RSV vaccination cuts infant hospitalisation risk by over 80%, major UKHSA study finds
- CGTN: Ako kultrne vmeny podporuj nsko-vietnamsk priatestvo
